Creative Planning’s VanEck Biotech ETF BBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $257K | Buy |
1,263
+12
| +1% | +$2.26K | ﹤0.01% | 3693 |
|
|
2026
Q1 | $235K | Sell |
1,251
-142
| -10% | -$27.4K | ﹤0.01% | 3620 |
|
|
2025
Q4 | $264K | Buy |
1,393
+2
| +0.1% | +$370 | ﹤0.01% | 3338 |
|
|
2025
Q3 | $231K | Buy |
1,391
+15
| +1% | +$2.45K | ﹤0.01% | 3357 |
|
|
2025
Q2 | $211K | Sell |
1,376
-367
| -21% | -$54.7K | ﹤0.01% | 3179 |
|
|
2025
Q1 | $274K | Sell |
1,743
-366
| -17% | -$59.4K | ﹤0.01% | 2839 |
|
|
2024
Q4 | $331K | Buy |
2,109
+265
| +14% | +$44.6K | ﹤0.01% | 2575 |
|
|
2024
Q3 | $327K | Sell |
1,844
-92
| -5% | -$16.3K | ﹤0.01% | 2451 |
|
|
2024
Q2 | $326K | Buy |
1,936
+41
| +2% | +$6.71K | ﹤0.01% | 2281 |
|
|
2024
Q1 | $315K | Buy |
1,895
+264
| +16% | +$43.7K | ﹤0.01% | 2210 |
|
|
2023
Q4 | $270K | Buy |
1,631
+1,156
| +243% | +$178K | ﹤0.01% | 2164 |
|
|
2023
Q3 | $74K | Buy |
+475
| New | +$75.9K | ﹤0.01% | 2435 |
|
|
2022
Q4 | – | Sell |
-1,501
| Closed | -$211K | – | 2499 |
|
|
2022
Q3 | $211K | Buy |
1,501
+100
| +7% | +$15.1K | ﹤0.01% | 1871 |
|
|
2022
Q2 | $204K | Sell |
1,401
-60
| -4% | -$8.94K | ﹤0.01% | 1870 |
|
|
2022
Q1 | $237K | Sell |
1,461
-364
| -20% | -$59K | ﹤0.01% | 1786 |
|
|
2021
Q4 | $346K | Buy |
1,825
+275
| +18% | +$53K | ﹤0.01% | 1523 |
|
|
2021
Q3 | $313K | Buy |
1,550
+5
| +0.3% | +$1.05K | ﹤0.01% | 1566 |
|
|
2021
Q2 | $312K | Sell |
1,545
-50
| -3% | -$9.31K | ﹤0.01% | 1540 |
|
|
2021
Q1 | $280K | Sell |
1,595
-193
| -11% | -$34.9K | ﹤0.01% | 1835 |
|
|
2020
Q4 | $303K | Buy |
1,788
+137
| +8% | +$22.6K | ﹤0.01% | 1629 |
|
|
2020
Q3 | $268K | Buy |
1,651
+372
| +29% | +$60.5K | ﹤0.01% | 1493 |
|
|
2020
Q2 | $208K | Buy |
+1,279
| New | +$194K | ﹤0.01% | 1502 |
|
|
2017
Q4 | – | Sell |
-18,016
| Closed | -$2.42M | – | 1908 |
|
|
2017
Q3 | $2.42M | Sell |
18,016
-29
| -0.2% | -$3.78K | 0.01% | 405 |
|
|
2017
Q2 | $2.27M | Sell |
18,045
-85
| -0.5% | -$10.2K | 0.01% | 406 |
|
|
2017
Q1 | $2.16M | Buy |
18,130
+30
| +0.2% | +$3.51K | 0.01% | 398 |
|
|
2016
Q4 | $1.95M | Hold |
18,100
| – | – | 0.01% | 415 |
|
|
2016
Q3 | $2.08M | Sell |
18,100
-3,500
| -16% | -$399K | 0.01% | 371 |
|
|
2016
Q2 | $2.21M | Sell |
21,600
-188
| -0.9% | -$20.1K | 0.02% | 313 |
|
|
2016
Q1 | $2.26M | Buy |
21,788
+1,200
| +6% | +$125K | 0.02% | 289 |
|
|
2015
Q4 | $2.61M | Sell |
20,588
-300
| -1% | -$36.8K | 0.02% | 257 |
|
|
2015
Q3 | $2.39M | Sell |
20,888
-2,201
| -10% | -$291K | 0.02% | 260 |
|
|
2015
Q2 | $3.11M | Buy |
23,089
+3,894
| +20% | +$518K | 0.03% | 209 |
|
|
2015
Q1 | $2.49M | Buy |
19,195
+1,600
| +9% | +$201K | 0.02% | 242 |
|
|
2014
Q4 | $2.03M | Sell |
17,595
-211
| -1% | -$23.8K | 0.02% | 267 |
|
|
2014
Q3 | $1.89M | Sell |
17,806
-100
| -0.6% | -$10.1K | 0.02% | 255 |
|
|
2014
Q2 | $1.71M | Buy |
17,906
+100
| +0.6% | +$8.96K | 0.02% | 258 |
|
|
2014
Q1 | $1.62M | Buy |
+17,806
| New | +$1.73M | 0.02% | 242 |
|
|
2013
Q4 | – | Sell |
-75
| Closed | -$6K | – | 3313 |
|
|
2013
Q3 | $6K | Buy |
+75
| New | +$5.89K | ﹤0.01% | 2650 |
|
Other funds holding BBH
MIM
CCA
BFG
Creative Planning's BBH Position: Q2 2026 in Review
Creative Planning increased its VanEck Biotech ETF (BBH) stake by 0.96% in Q2 2026, buying an estimated $2.26K and bringing the position to 1,263 shares worth $257K. The position accounts for ﹤0.01% of the portfolio, ranked #3693.
Creative Planning first reported a position in BBH in Q3 2013 and has held it in 38 quarters since. The position peaked at $3.11M in Q2 2015. 110 funds tracked by Wall St. Rank hold BBH as of Q2 2026.
- Creative Planning held 1,263 shares of VanEck Biotech ETF worth $257K as of Q2 2026.
- Creative Planning bought 12 VanEck Biotech ETF shares in Q2 2026, an estimated $2.26K.
- VanEck Biotech ETF made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3693 holding.
- Creative Planning first reported a position in VanEck Biotech ETF in Q3 2013 and has held it in 38 quarters since.
- Creative Planning's VanEck Biotech ETF position peaked at $3.11M in Q2 2015.
- 110 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2026.
Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.